NeuroPace (NPCE) announced completion of enrollment and implant procedures in its feasibility investigational device exemption, or IDE, study of the RNS System for the treatment of Lennox-Gastaut Syndrome, or LGS, a devastating form of childhood-onset epilepsy characterized by cognitive dysfunction and frequent generalized onset seizures that often lead to injury.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter